지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2025.2
- 수록면
- 72 - 78 (7page)
이용수
초록· 키워드
오류제보하기
Backgrounds/Aims: Irreversible electroporation (IRE) may have a potential application as either a “back-up therapy” or for margin accentuation during trial dissection of locally advanced pancreatic cancer (LAPC). The aim of this report was to describe our experi- ence with IRE in terms of its potential applications mentioned above.
Methods: A clinical policy to use IRE in LAPC patients undergoing exploratory surgery after neoadjuvant therapy (NAT) was initi- ated in 2017. If resection was feasible, IRE was used for margin accentuation. If not, then IRE was undertaken as a “back-up therapy” of non-resectable tumor. Data on baseline characteristics, perioperative 90-day morbidity, recurrence-free survival (RFS) and overall survival (OS) were collected.
Results: IRE was successfully performed in 18 (95%) patients. IRE was abandoned in one case for technical reasons. Nine patients who were found to have an unresectable disease underwent IRE as a “back-up therapy” while the remaining patients received IRE for margin accentuation. Complications were recorded in 33% patients. There was no procedure-related mortality. In the group receiving IRE for margin accentuation, the median RFS was 10.0 months (range, 4.5–15.0 months). The median OS of our cohort was 22 months (range, 14.75–27.50 months).
Conclusions: This report shows that in patients with LAPC undergoing exploratory surgery following NAT, IRE seems technically feasible for margin accentuation or as a “back-up therapy”. More data are needed to determine procedure-related morbidity, mortality, and any effects of IRE on cancer-related survival.
Methods: A clinical policy to use IRE in LAPC patients undergoing exploratory surgery after neoadjuvant therapy (NAT) was initi- ated in 2017. If resection was feasible, IRE was used for margin accentuation. If not, then IRE was undertaken as a “back-up therapy” of non-resectable tumor. Data on baseline characteristics, perioperative 90-day morbidity, recurrence-free survival (RFS) and overall survival (OS) were collected.
Results: IRE was successfully performed in 18 (95%) patients. IRE was abandoned in one case for technical reasons. Nine patients who were found to have an unresectable disease underwent IRE as a “back-up therapy” while the remaining patients received IRE for margin accentuation. Complications were recorded in 33% patients. There was no procedure-related mortality. In the group receiving IRE for margin accentuation, the median RFS was 10.0 months (range, 4.5–15.0 months). The median OS of our cohort was 22 months (range, 14.75–27.50 months).
Conclusions: This report shows that in patients with LAPC undergoing exploratory surgery following NAT, IRE seems technically feasible for margin accentuation or as a “back-up therapy”. More data are needed to determine procedure-related morbidity, mortality, and any effects of IRE on cancer-related survival.
목차
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors
Annals of Hepato-Biliary-Pancreatic Surgery
2016 .08
-
Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study
Investigative and Clinical Urology
2022 .05
-
Novel Ablation Therapy Using Endoscopic Irreversible Electroporation in the Bile Duct: A Pilot Animal Study
Clinical Endoscopy
2021 .01
-
D-Allulose ameliorates hyperglycemia through IRE1α sulfonation-RIDD- sirt1 decay axis in the skeletal muscle
한국실험동물학회 학술발표대회 논문집
2022 .07
-
국소 진행성 췌장암에서의 내시경적 국소 치료
대한췌담도학회지
2020 .01
-
Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data
Annals of Hepato-Biliary-Pancreatic Surgery
2018 .11
-
Oncologic outcomes according to the location and status of resection margin in pancreas head cancer: role of radiation therapy in R1 resection
Annals of Surgical Treatment and Research
2022 .01
-
Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
Annals of Surgical Treatment and Research
2017 .10
-
Neoadjuvant chemotherapy followed by total pancreatectomy with splenectomy and combined vascular resections after preoperative percutaneous transhepatic portal vein stent placement in locally advanced pancreatic cancer with portal vein total obliteration
Annals of Hepato-Biliary-Pancreatic Surgery
2020 .11
-
Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
Gut and Liver
2022 .01
-
Current status of neoadjuvant therapy for pancreas cancer
대한임상종양학회 학술대회지
2021 .06
-
Role of Inositol-Requiring Enzyme 1 and Autophagy in the Pro-Fibrotic Mechanism Underlying Graves’ Orbitopathy
Yonsei Medical Journal
2024 .07
-
Treatment options for stable locally advanced pancreatic cancer after chemotherapy
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis
Cancer Research and Treatment
2017 .07
-
Modifications to Treatment Plan of Rectal Cancer in Response to COVID-19 at the Philippine General Hospital
Annals of Coloproctology
2021 .08
-
Survival improvement in locally advanced pancreatic cancer after FOLFIRINOX neoadjuvant treatment and conversion surgery
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Cancer Research and Treatment
2021 .01
-
Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .05
-
The change of clinical stage after neoadjuvant chemotherapy in prediction of prognosis for borderline resectable and locally advanced pancreatic cancer
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Corrigendum to: Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
Gut and Liver
2023 .03
이 논문과 함께 이용한 논문
Clinical Significance of Serum Lactate Dehydrogenase as a Diagnostic Marker in Breast Cancer Patients
Eun You Kim
,
Dong Hyeok Kim
,
Hyunwoo Jin
외 1명
생명과학회지
2025
.02
Development and Validation of the Short Form of Core Competencies Scale of Nursing Care for Cancer Patients Undergoing Chemotherapy
Kim
,
Sung Hae
,
Lee
외 7명
Asian Oncology Nursing
2024
.12
Next-generation sequencing of BRCA1/2 in breast cancer patients : potential effects on clinical decision-making using rapid, high-accuracy genetic results
Hyung Seok Pa
,
k
,
Seo-Jin Pa
외 11명
Annals of Surgical Treatment and Research
2017
.05
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-151-25-02-092320252